- Home
- AMSF vs VIR Comparison
AMSF vs VIR Comparison
Compare AMSF & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- VIR
- Stock Information
- Founded
- AMSF 1985
- VIR 2016
- Country
- AMSF United States
- VIR United States
- Employees
- AMSF N/A
- VIR N/A
- Industry
- AMSF Accident &Health Insurance
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- VIR Health Care
- Exchange
- AMSF Nasdaq
- VIR Nasdaq
- Market Cap
- AMSF 869.6M
- VIR 844.9M
- IPO Year
- AMSF 2005
- VIR 2019
- Fundamental
- Price
- AMSF $43.75
- VIR $5.13
- Analyst Decision
- AMSF Buy
- VIR Strong Buy
- Analyst Count
- AMSF 2
- VIR 7
- Target Price
- AMSF $59.50
- VIR $32.86
- AVG Volume (30 Days)
- AMSF 151.1K
- VIR 1.1M
- Earning Date
- AMSF 07-28-2025
- VIR 07-31-2025
- Dividend Yield
- AMSF 10.47%
- VIR N/A
- EPS Growth
- AMSF N/A
- VIR N/A
- EPS
- AMSF 2.48
- VIR N/A
- Revenue
- AMSF $301,216,000.00
- VIR $20,861,000.00
- Revenue This Year
- AMSF $1.69
- VIR N/A
- Revenue Next Year
- AMSF $6.54
- VIR N/A
- P/E Ratio
- AMSF $17.57
- VIR N/A
- Revenue Growth
- AMSF N/A
- VIR N/A
- 52 Week Low
- AMSF $42.68
- VIR $4.32
- 52 Week High
- AMSF $60.24
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- AMSF 35.39
- VIR 48.62
- Support Level
- AMSF $42.84
- VIR $5.00
- Resistance Level
- AMSF $44.54
- VIR $5.35
- Average True Range (ATR)
- AMSF 0.79
- VIR 0.24
- MACD
- AMSF -0.07
- VIR 0.02
- Stochastic Oscillator
- AMSF 17.83
- VIR 31.21
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.